Full Press Release Details
Approval for BiondVax:
Receives Approval for a Patent for its Universal
Flu Vaccine in Israel
patent approval extends and strengthens BiondVax's international intellectual property portfolio
Pharmaceuticals Ltd. (NASDAQ: BVXV, TASE: BVXV)
which is developing the Universal Flu Vaccine, announced today that its patent application in Israel on the Multimeric Multi-Epitope
Polypeptide Influenza Vaccines (a universal flu vaccine), was accepted.
patent application belongs to the main family of patents of BiondVax for vaccination against influenza in humans, and specifically
vaccines that confer long-lasting protection against multiple and differing flu strains. The Israeli Intellectual Property Office
accepted BiondVax's claims for M-001 (BiondVax's universal flu vaccine) and similar polypeptides.
protection has already been granted in a number of other countries, namely the United States, Europe, Japan, Hong Kong, Australia,
China, Russia, Mexico and Korea.
Babecoff, CEO of BiondVax said "We are very pleased that the Israeli patent authorities accepted the uniqueness of our
universal flu vaccine solution, approving this main patent of BiondVax. Our solution is patent protected in many of the countries
where we believe our vaccine will provide increased protection to the local population from flu, including multiple European countries,
in the United States and in the Far East."
BiondVax Pharmaceuticals Ltd
is an innovative biopharmaceutical company developing a universal flu vaccine, designed to provide multi-season and multi-strain
protection against most human influenza virus strains, including both seasonal and pandemic flu strains.
technology utilizes a unique, proprietary combination of conserved and common peptides from influenza virus proteins to activate
both arms of the immune system for a cross-protecting and long-lasting effect.
Science Park, 14 Einstein Street, PO Box 4143, Nes Ziona 74140, Israel
Tel: +972 8 930 2529 Fax:+972 8 930 2531 www.biondvax.com
press release contains forward-looking statements within the meaning of the Private Litigation Reform Act of 1995. Words such
as "expect," "believe," "intend," "plan," "continue," "may," "will,"
"anticipate," and similar expressions are intended to identify forward-looking statements. These forward-looking statements
involve certain risks and uncertainties reflect the management's current views with respect to certain current and future events
and are subject to various risks, uncertainties and assumptions that could cause the results to differ materially from those expected
by the management of BiondVax Pharmaceuticals Ltd. risks and uncertainties include, but are not limited to, the risk that drug
development involves a lengthy and expensive process with uncertain outcome, BiondVax's ability to continue obtaining and
maintaining intellectual property protection for our Universal Flu Vaccine, risks inherent in the development and commercialization
of potential products, dependence upon collaborators, and adequacy of capital resources for product development and commercialization.
The risks, uncertainties and assumptions referred to above are discussed in detail in our reports filed with the Securities and
Exchange Commission, including our Prospectus which was declared effective on May 11, 2015. BiondVax Pharmaceuticals Ltd. undertakes
no obligation to update or revise any forward-looking statements.
further information, please contact:
Science Park, 14 Einstein Street, PO Box 4143, Nes Ziona 74140, Israel
Tel: +972 8 930 2529 Fax:+972 8 930 2531 www.biondvax.com